ClinicalTrials.gg
CompletedNCT02284139Updated Apr 23, 2018

Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects

A Phase 2/3 interventional study of Arm EGF ointment 1ppm and Arm EGF ointment 20 ppm in Non-small Cell Lung Cancer, Pancreatic Cancer and Colorectal Cancer, sponsored by Dong-A University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-04-23.

Sponsored by Dong-A University Hospital · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 702 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of — 124 open to participants now, 264 under way, 101 of them phase 3. Carcinoma, Non-Small-Cell Lung · Korea, Republic of.

Enrollment
480th of 659
90 · median 200
Started
2015
with 39 others
Phase 2/3
14 of 702
5 open now
Registered
204th of 702
by date

Among the 702 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of, this one is the 480th largest by enrollment of the 659 interventional ones that give a count, is one of 40 that started in 2015, is one of 14 in phase 2/3, and was the 204th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

124 of the 702 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 702 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The efficacy of the epidermal growth factor receptor (EGFR) inhibitors have been demonstrated in patients with non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and colorectal cancer (CRC). Dermatological reactions can cause significant physical and psycho-social discomfort to patients. In the present study, the investigators evaluated the effect of epidermal growth factor (EGF) ointment on EGFR inhibitor-related skin side effects (ERSEs).

Read the detailed description

The current study includes patients diagnosed with advanced NSCLC or PC or CRC, with pathological confirmation. The inclusion criteria were NSCLC treated with erlotinib alone and PC treated with gemcitabine and erlotinib combination chemotherapy and CRC treated with cetuximab and5-Fluorouracil (5-FU)+Irinotecan+leucovorin(LV) (FOLFIRI), 5-FU+Oxaliplatin+LV (FOLFOX) and sufficient liver, kidney, and bone marrow function to undergo treatment. All the patients had Grade ≥2 ERSEs according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) v. 4.03.

The patients will be randomized 3 groups; Placebo group, Arm 1, and Arm 2. Arm 1 will be treated with 1ppm concentration EGF ointment. Arm 2 will be treated with 20ppm concentration EGF ointment. And placebo group will be treated with 0ppm concentration EGF ointment.

03

Conditions studied

  • Non-small Cell Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer

Keywords

  • EGF ointment
  • EGFR inhibitor
  • Skin side effect
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: older than 20
  2. (ECOG) performance status 0 -2
  3. confirmed lung cancer, pancreatic cancer, or colon cancer
  4. Patients take EGFR inhibitor following the reason

    • EGFR mutation (+) NSCLC - adenocarcinoma for treatment
    • NSCLC - for ≥ 2nd line treatment
    • Pancreatic cancer - adenocarcinoma for 1st line treatment with Gemcitabine
    • Colon cancer - adenocarcinoma 1st line treatment with Irinotecan (FOLFIRI)
  5. Patients who have EGFR inhibitor related skin side effects (ERSE) Gr≥2 (NCICTC V4.0)
  6. A patient with the willingness to comply with the study protocol during the study period and capable of complying with it
  7. A patient who signed the prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages

Exclusion criteria

Exclusion Criteria:

  1. A patient with previous active or passive immunotherapy
  2. A pregnant or lactating patient
  3. A patient of without being tested for pregnancy at baseline for positive. (A woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential.)
  4. A patient with history of uncontrolled seizures, central nervous system disorder or psychiatric disorders that are considered by the investigator that would prohibit the understanding of or that may be considered to interfere with the compliance of the administration of the study medications
  5. A patient with history of dermatologic care (except transient urticaria) within 4 weeks
  6. A patient with clinically significant (i.e. active) heart disease (e.g. congestive heart failure, symptomatic coronary artery diseases, cardiac arrhythmias, etc) or myocardial infarction within past 12 months
  7. A patient with interstitial pneumonia or diffused symptomatic fibrosis of the lungs.
  8. Organ allogenic transplantation requiring therapy. Any waiver of these inclusion and exclusion criteria must be approved by the investigator and the sponsor on a case-by case basis prior to enrolling the subject
  9. Known allergies, , or intolerance to study drugs, chemotherapy drugs using this clinical trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo ointment dose not contain EGF.

    Drug: Arm Placebos

  • Active comparator
    Arm EGF ointment 1ppm

    Arm EGF ointment 1ppm will be treated with EGF ointment of 1 ppm concentration

    Drug: Arm EGF ointment 1ppm

  • Active comparator
    Arm EGF ointment 20ppm

    Arm EGF ointment 20ppm will be treated with EGF ointment of 20 ppm concentration

    Drug: Arm EGF ointment 20 ppm

Interventions

  • DrugArm EGF ointment 1ppm

    EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day

    Also known as: Saesal yeongo 1 (EGF ointment 1ppm)

  • DrugArm EGF ointment 20 ppm

    EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day

    Also known as: Saesal yeongo 20 (EGF ointment 20 ppm)

  • DrugArm Placebos

    EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day

    Also known as: Saesal yeongo 0 (EGF ointment 0 ppm)

06

What researchers measure

Primary outcomes

  1. To estimate the response rate of EGF ointment

    The effectiveness of the EGF ointment was defined as follows: 1. Grade 2, 3, or 4 ERSEs downgraded to ≤Grade 1 or 2. Grade 3 or 4 ERSEs downgraded to Grade 2 and persisting for at least two weeks.

    Time frame: 1 year

Secondary outcomes

  1. Quality of Life

    To evaluate the patients' Quality of Life (QoL) by Skin evaluation method (SKINDEX-16)

    Time frame: 1 year

07

Study locations

1 site
  • Sung Yong Oh
    Busan, 602-715, Korea, Republic of
08

References and documents

Publications

  • Kim YS, Ji JH, Oh SY, Lee S, Huh SJ, Lee JH, Song KH, Son CH, Roh MS, Lee GW, Lee J, Kim ST, Kim CK, Jang JS, Hwang IG, Ahn HK, Park LC, Oh SY, Kim SG, Lee SC, Lim DH, Lee SI, Kang JH. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities. Oncologist. 2020 Jan;25(1):e186-e193. doi: 10.1634/theoncologist.2019-0221. Epub 2019 Sep 6. PubMed 31492766 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Dec 2016, 20 months.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2014
First posted
Nov 5, 2014
StartActual
Apr 2015
Primary completionActual
Dec 2016
CompletionActual
Dec 2017
Last update
Apr 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02284139
Lead sponsor
Dong-A University Hospital
Responsible party
Sung Yong Oh (Department of Internal Medicine, Dong-A University Hospital, Dong-A University Hospital) — Principal investigator
First posted
Nov 5, 2014
Start date
Apr 2015
Primary completion
Dec 2016
Completion
Dec 2017
Last update
Apr 23, 2018

Study contacts

SUNG YONG OH, M.D.
principal investigator · Dong-A University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion